How to buy Ginkgo Bioworks stock in Canada

Ginkgo Bioworks plans to go public by merging with special purpose acquisition company (SPAC), Soaring Eagle Acquisition Corp. But there’s no word yet on its anticipated release date or projected share price. Here's how investors in Canada can prepare to buy in when Ginkgo Bioworks finally goes public.

Our top picks for where to buy Ginkgo Bioworks stock

Buy Ginkgo Bioworks stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Note: The dollar amounts in the table below are in Canadian dollars.

Finder Score for stock trading platforms

To make comparing even easier we came up with the Finder Score. Trading costs, account fees and features across 10+ stock trading platforms and apps are all weighted and scaled to produce a score out of 10. The higher the score the better the platform - simple.

Read the full methodology

Related: Compare the best stock trading platforms in Canada

Ginkgo Bioworks stock price (NYSE: DNA)

Use our graph to track the performance of DNA stocks over time.

Ginkgo Bioworks stocks at a glance

• Key figures

Information last updated 2025-06-15.

Latest market close	$8.55
52-week range	$5.00 - $18.55
50-day moving average more info button	$7.53
200-day moving average more info button	$8.57
Wall St. target price	$9.00
PE ratio more info button	N/A
Dividend yield more info button	N/A
Earnings per share (TTM) more info button	$-8.91

Is it a good time to buy Ginkgo Bioworks stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Dive deeper: Our picks for the best stocks to buy right now in Canada

Ginkgo Bioworks financials

Revenue TTM	$237.4 million
Gross profit TTM	$190 million
Return on assets TTM	-16.99%
Return on equity TTM	-57.76%
Profit margin	-198.84%
Book value	$11.84
Market Capitalization more info button	$523.3 million

TTM: trailing 12 months

Ginkgo Bioworks stock dividends

We're not expecting Ginkgo Bioworks to pay a dividend over the next 12 months.

Have Ginkgo Bioworks's stocks ever split?

Ginkgo Bioworks's stocks were split on a 1:40 basis on 19 August 2024 . So if you had owned 40 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Ginkgo Bioworks stocks – just the quantity. However, indirectly, the new 3900% higher stock price could have impacted the market appetite for Ginkgo Bioworks stocks, which in turn could have impacted Ginkgo Bioworks's stock price.

Ginkgo Bioworks stock price volatility

Over the last 12 months, Ginkgo Bioworks's stocks have ranged in value from as little as $5 up to $18.552. A popular way to gauge a stock's volatility is its "beta."

Beta is a measure of a stocks volatility in relation to the market. The market (NYSE average) beta is 1, while Ginkgo Bioworks's is 1.257. This would suggest that Ginkgo Bioworks's stocks are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Ginkgo Bioworks overview

Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops a platform for cell programming in the United States. It operates through Cell Engineering and Biosecurity segments. The company offers cell engineering research and development solutions, as well as cell engineering tools comprising functional genomics and antibody developability Datapoints services, artificial intelligence models, and reconfigurable automation cart systems on its platform for use in the research, development, and commercialization of engineered organisms and derived products. It also provides biomonitoring and bioinformatics support services through Canopy, which generates genomic data from strategically positioned nodes through biomonitoring programs; and Horizon, a digital surveillance, analytics, and insights platform that detects and monitors biothreats. The company serves the pharmaceutical and biotechnology, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries. Ginkgo Bioworks Holdings, Inc.

Related: New to stock trading? Compare brokers and get tips for investing.

Frequently asked questions

What percentage of Ginkgo Bioworks is owned by insiders or institutions?
Currently 6.685% of Ginkgo Bioworks stocks are held by insiders and 79.412% by institutions. How many people work for Ginkgo Bioworks?
Latest data suggests 834 work at Ginkgo Bioworks. When does the fiscal year end for Ginkgo Bioworks?
Ginkgo Bioworks's fiscal year ends in December. Where is Ginkgo Bioworks based?
Ginkgo Bioworks's address is: 27 Drydock Avenue, Boston, MA, United States, 02210 What is Ginkgo Bioworks's ISIN number?
Ginkgo Bioworks's international securities identification number is: US37611X2099 What is Ginkgo Bioworks's CUSIP number?
Ginkgo Bioworks's Committee on Uniform Securities Identification Procedures number is: 37611X100

Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.